The corruption of the FDA's scientific culture is driving the deterioration of safety and effectiveness standards, David Ross, MD, associate clinical professor of medicine at Washington, D.C.-based George Washington University School of Medicine and Health Sciences, wrote in an opinion…

CVS Pharmacy has agreed to pay $6.15 million to resolve allegations that the company in some instances failed to follow prescription pricing procedures set by Massachusetts' workers' compensation insurance program.

The Supreme Court declined to hear Teva Pharmaceuticals USA's challenge to a $235 million award to GlaxoSmithKline in a patent dispute over a generic heart drug.

The Federal Trade Commission has filed an injuction in federal court seeking to block Amgen's acquisition of fellow drugmaker Horizon Therapeutics. 

Rising popularity of Novo Nordisk's Ozempic is making it more difficult to find, leaving some patients to turn to unauthorized alternatives, The New York Times reported May 16. 

A universal flu vaccine that protects against all known strains of the virus — both seasonal and pandemic — is now undergoing a phase 1 trial at Duke University in Durham, N.C. 

Drugmaker Novartis announced 10 members to its newly formed Sandoz board of directors May 15 ahead of its previously announced biosimilar spinoff. The Sandoz spinoff is an effort the company is making to keep a competitive pace with rising costs…

The FDA on May 12 approved Astellas' Veozah — a once-a-day pill meant to treat hot flashes associated with menopause. 

Illinois' top public health leader issued a standing order May 11, allowing pharmacists in the state to dispense hormonal contraception.

Eisai and Biogen's new Alzheimer's drug Leqembi could cost Medicare an estimated $2 billion to $5 billion annually, according to a study published May 11 in JAMA Internal Medicine.